Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

February 22, 2023Open Access

A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)

HYHiroshi YotsuyanagiNihon University NONorio OhmagariNational Center for Global Health and Medicine YDYohei DoiFujita Health University

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In a post hoc analysis of the phase 2b study, compared with placebo, ensitrelvir demonstrated a reduced time to resolution of 5 symptoms in patients with mild-to-moderate COVID-19. Through this study, we intend to validate and establish the efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Yotsuyanagi et al. (Wed,) studied this question.

synapsesocial.com/papers/69de84dd7ed287395e5596e5 https://doi.org/https://doi.org/10.1097/md.0000000000033024

A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part) | Synapse

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study2022 · 10 citations
2Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-192022 · 593 citations
3COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses2020 · 3,640 citations
4The statistical analysis of failure time data1981 · 1,390 citations
5Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis2020 · 2,201 citations